CancerThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• Contents
• Discussions

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  

ErratumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No abstract. (Source: Cancer)
Source: Cancer - November 21, 2009 Category: Cancer & Oncology Source Type: journals

Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Generally, the blood-brain barrier (BBB) of brain metastasis was thought to be disrupted.We retrospectively performed immunohistochemical staining for glucose transporter 1 (GLUT1) and breast cancer resistance protein (BCRP) to evaluate the status of the BBB in resected brain metastases. Associations between expression of GLUT1 and/or BCRP and the immunohistochemical profiles of breast cancers, such as the statuses of hormone receptors, human epidermal growth factor receptor 2 (HER2/neu), and a basal-type marker (cytokeratin 5/6, HER1), were also analyzed.The study included 29 breast cancer patients with brain metastasis w...
Source: Cancer - November 20, 2009 Category: Cancer & Oncology Authors: Kan Yonemori, Koji Tsuta, Makiko Ono, Chikako Shimizu, Akihiro Hirakawa, Tadashi Hasegawa, Yutaka Hatanaka, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara Source Type: journals

The impact of health insurance status on the survival of patients with head and neck cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this study was to examine whether cancer recurrence and mortality of patients diagnosed with squamous cell carcinoma of the head and neck are associated with insurance status, after adjusting for known cancer risk factors. The main outcome measures were overall survival and relapse-free survival.Retrospective cohort of patients with a biopsy-proven primary squamous cell carcinoma of the oral cavity, pharynx, or larynx diagnosed or treated at the University of Pittsburgh Medical Center between 1998 and 2007. Patients were stratified by their insurance status, including private insurance, uninsured/Medicaid,...
Source: Cancer - November 20, 2009 Category: Cancer & Oncology Authors: Joseph Kwok, Scott M. Langevin, Athanassios Argiris, Jennifer R. Grandis, William E. Gooding, Emanuela Taioli Source Type: journals

Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The purpose of this study was to confirm whether black and white women with endometrial cancer are equally tolerant of chemotherapy and identify factors that impact survival.A retrospective review of 169 black women and 982 white women with the International Federation of Gynecologists and Obstetricians stage III, stage IV, or recurrent endometrial carcinoma was performed. All patients received doxorubicin combined with cisplatin. Chemotherapy parameters that were reviewed included relative dose, relative time, and relative dose intensity. Treatment cycles [ge]7 were defined as treatment completion.Although black patients ...
Source: Cancer - November 19, 2009 Category: Cancer & Oncology Authors: John H. Farley, Chunqiao Tian, G. Scott Rose, Carol L. Brown, Michael Birrer, John I. Risinger, J. Tate Thigpen, Gini F. Fleming, Holly H. Gallion, G. Larry Maxwell Source Type: journals

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dasatinib, a highly potent BCR-ABL inhibitor, is an effective treatment for patients with chronic myeloid leukemia in chronic phase (CML CP) after resistance, suboptimal response, or intolerance to prior imatinib. In a phase 3 dose optimization trial in patients with CML CP (CA180-034), the occurrence of pleural effusion was significantly minimized with dasatinib 100 mg once daily (QD) compared with other treatment arms (70 mg twice daily [twice daily], 140 mg QD, or 50 mg twice daily).To investigate the occurrence and management of pleural effusion during dasatinib treatment, and efficacy in patients with or without pleur...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Kimmo Porkka, H. Jean Khoury, Ronald L. Paquette, Yousif Matloub, Ritwik Sinha, Jorge E. Cortes Source Type: journals

Isolated limb infusion with cytotoxic agents: A simplified approach for venous accessEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Isolated limb infusion (ILI) of cytotoxic agents is a regional therapy for cutaneous malignancies in a single extremity. Conventional ILI technique requires retrograde catheterization of the contralateral femoral vein. A novel modified ILI technique uses an ipsilateral popliteal venous approach. The purpose of this study was to compare the performance of ILI using the 2 different approaches.Data from patients who underwent lower-extremity ILI at the authors' institution between October 2005 and June 2008 were retrospectively reviewed. The authors compared the 2 ILI approaches with regard to overall procedure time, fluorosc...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Ajit Vyas, Rony Avritscher, Joe Ensor, Merrick Ross, Michael J. Wallace Source Type: journals

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
was investigated.We analyzed 120 patients registered into the European Ewing Tumor Working Initiative of National Groups (EURO-E.W.I.N.G. 99) trial at the trial center of Muenster from 1998 to 2006. Median age was 16.2 years. Local treatment of the primary tumor was surgery in 26 of 120 patients, surgery and radiotherapy in 21 patients, and definitive radiotherapy in 40 patients. For treatment of metastases, 6 of 120 patients received surgery; 9 patients, surgery and radiotherapy; and 33 patients, definitive radiotherapy. Forty-seven (39%) patients had local treatment of both the primary tumor and metastases, 41 (34%) pat...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Julia Haeusler, Andreas Ranft, Tobias Boelling, Georg Gosheger, Gabriele Braun-Munzinger, Volker Vieth, Stefan Burdach, Henk van den Berg, Heribert Juergens, Uta Dirksen Source Type: journals

Methadone initiation and rotation in the outpatient setting for patients with cancer painEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Methadone is an effective and inexpensive opioid for cancer pain treatment. It has been reported as difficult to use in the outpatient setting because of its variable relative potency and long half-life. The purpose of this study was to determine the outcome of methadone initiation or rotation for cancer pain treatment in outpatient settings.Chart review was done of 189 consecutive patients who underwent methadone initiation or rotation at the authors' palliative care outpatient center. Data were collected regarding demographic and clinical characteristics, symptoms, and opioid side effects at baseline and for 2 follow-up ...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Henrique A. Parsons, Maxine de la Cruz, Badi El Osta, Zhijun Li, Bianca Calderon, J. Lynn Palmer, Eduardo Bruera Source Type: journals

Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benignEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Correct pretreatment classification is critical for optimizing diagnosis and treatment of patients with peripheral nerve sheath tumors (PNSTs). The aim of this study was to evaluate whether F18-fluorodeoxyglucose positron emission tomography (FDG PET) can differentiate malignant (MPNST) from benign PNSTs.Thirty-four adult patients presenting with PNST who underwent a presurgical FDG PET/computed tomography (CT) scan between February 2005 and November 2008 were included in the study. Tumors were characterized histologically, by FDG maximum standardized uptake value (SUVmax [g/mL]), and by CT size (tumor maximal diameter [cm...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Matthias R. Benz, Johannes Czernin, Sarah M. Dry, William D. Tap, Martin S. Allen-Auerbach, David Elashoff, Michael E. Phelps, Wolfgang A. Weber, Fritz C. Eilber Source Type: journals

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
HER-2/neu, overexpressed in breast cancer, is a source of immunogenic peptides that include GP2 and E75. Phase 2 testing of E75 as an adjuvant vaccine has suggested a clinical benefit. GP2, derived from the transmembrane portion of HER-2/neu, has differing binding characteristics and may be more immunogenic than E75. Results of the first phase 1 trial of GP2 peptide vaccine are presented.Disease-free, lymph node-negative, human leukocyte antigen (HLA)-A2+ breast cancer patients were enrolled. This dose escalation trial included 4 groups to determine safety and optimal GP2 peptide/granulocyte-macrophage colony-stimulating f...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Mark G. Carmichael, Linda C. Benavides, Jarrod P. Holmes, Jeremy D. Gates, Elizabeth A. Mittendorf, Sathibalan Ponniah, George E. Peoples Source Type: journals

We need better randomized comparison trials of prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
More than 50 years after the first randomized oncology trial, the number of randomized trials comparing differing primary treatments for prostate cancer is disappointing. One of these rare, randomized primary treatment comparisons appears in this edition of Cancer, and the investigators are to be congratulated for their efforts comparing cryotherapy with external beam radiotherapy. (Source: Cancer)
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: W. Robert Lee Source Type: journals

Expression of interleukin 15 in primary adult acute lymphoblastic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Interleukin-15 (IL-15) has been associated with the growth, survival and biological behavior of leukemic cells and response to therapy. We determined the expression of IL-15 in lymphoblasts and evaluated its potential impact on the outcome in adult acute lymphoblastic leukemia (ALL).Between June 1999 and June 2006, ALL samples were collected from 87 adult patients before initiation of antineoplastic therapy. These patients were enrolled in the German Multicenter Acute Lymphoblastic Leukemia June 1999 and July 2003 study trials. The expression of IL-15 in leukemic cells was analyzed by real-time polymerase chain reaction.Th...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Shuling Wu, Lars Fischer, Nicola Gökbuget, Stefan Schwartz, Thomas Burmeister, Michael Notter, Dieter Hoelzer, Hendrik Fuchs, Igor Wolfgang Blau, Wolf K Hofmann, Eckhard Thiel Source Type: journals

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Salivary gland cancers are rare, histologically diverse, and varied in their biologic behavior and responsiveness to systemic therapy. To the authors' knowledge, there currently is no standard chemotherapy for these tumors, but cisplatin-based regimens are often used. This phase 2 trial evaluated the combination of gemcitabine with cisplatin (carboplatin in those with protocol-defined contraindications to cisplatin).Fit, consenting adult patients had advanced, metastatic, or locoregionally recurrent salivary gland cancer (any histologic subtype) that was not suitable for radiation or surgery. Therapy was comprised of gemci...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Scott A. Laurie, Lillian L. Siu, Eric Winquist, Andrew Maksymiuk, Erica L. Harnett, Wendy Walsh, Dongsheng Tu, Wendy R. Parulekar Source Type: journals

Urinary diversion and morbidity after radical cystectomy for bladder cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The rate of continent urinary diversion after radical cystectomy for bladder cancer varies by patient and provider characteristics. Demonstration of equivalent complication rates, independent of diversion type, may decrease provider reluctance to perform continent reconstructions. The authors sought to determine whether continent reconstructions confer increased complication rates after radical cystectomy.From the Nationwide Inpatient Sample, the authors used International Classification of Disease (ICD-9) codes to identify subjects who underwent radical cystectomy for bladder cancer during 2001-2005. They determined acute...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: John L. Gore, Hua-Yin Yu, Claude Setodji, Jan M. Hanley, Mark S. Litwin, Christopher S. Saigal, the Urologic Diseases in America Project Source Type: journals

Addressing cancer health disparities using a global biopsychosocial approachEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Center for Research on Minority Health has translated the biopsychosocial framework to address global cancer health disparities through the integration of biological (eg, endogenous steroids, genetic susceptibility, and pesticide levels) and behavioral (eg, dietary interventions) determinants, along with community-based research (eg, comprehensive involvement of community advisory boards) and educational approaches (eg, kindergarten through postgraduate training). Evidence of successful implementation of this framework includes health disparities training for >2000 individuals ranging from elementary to the postgraduat...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Denae King, Patricia Miranda, Beverly Gor, Robin Fuchs-Young, Janice Chilton, Richard Hajek, Isabel Torres-Vigil, Mariá A. Hernández-Valero, S. Amy Snipes, Lovell Jones Source Type: journals

Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myelomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Currently used treatment response criteria in multiple myeloma (MM) are based in part on serum monoclonal protein (M-protein) measurements. A drawback of these criteria is that response is determined solely by the best level of M-protein reduction, without considering the serial trend. The authors hypothesized that metrics incorporating the serial trend of M-protein would be better predictors of progression-free survival (PFS).Fifty-five patients with measurable disease at baseline (M-protein [ge]1 g/dL) who received [ge]4 cycles of treatment from 2 clinical trials in previously untreated MM were included. Three metrics ba...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Eric W. Schaefer, Shaji Kumar, Angela Dispenzieri, Jacob B. Allred, Morie A. Gertz, Martha Q. Lacy, S. Vincent Rajkumar, Sumithra J. Mandrekar Source Type: journals

A multidimensional examination of correlates of fatigue during radiotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of the current study was to investigate cancer-related fatigue in a radiotherapy sample using a multidimensional conceptualization to determine whether correlates of fatigue are consistent across all dimensions or whether each fatigue dimension has its own unique pattern of correlates.The study used a prospective cohort design with data collected from radiotherapy patients at 3 time points; before, after, and 6 weeks after radiotherapy treatment.A total of 210 participants were enrolled in the study. Results indicated the following relations. Increased general fatigue was found to be associated with lower per...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Amanda Purcell, Jennifer Fleming, Sally Bennett, Kathleen McGuane, Bryan Burmeister, Terry Haines Source Type: journals

Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Memorial Sloan-Kettering Cancer Center risk model classifies patients with metastatic renal cell carcinoma (RCC) by 5 pretreatment features as favorable, intermediate, and poor risk. The number of Memorial Sloan-Kettering Cancer Center patients in each risk group was examined by year of treatment to analyze stage migration.The distribution of risk groups was examined retrospectively in 789 Memorial Sloan-Kettering Cancer Center patients with metastatic RCC treated in a first-line therapy clinical trial from 1975 to 2007. Date of treatment onset was divided into 6 cohorts between 1975 and 2007 (1975-1980, 1981-1985, 198...
Source: Cancer - November 17, 2009 Category: Cancer & Oncology Authors: Sujata Patil, Nicole Ishill, John Deluca, Robert J. Motzer Source Type: journals

Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A significant response to placebo in randomized controlled trials of treatments for cancer-related fatigue (CRF) had been reported. A retrospective study was conducted to determine the frequency and predictors of response to placebo effect and nocebo effects in patients with CRF treated in those trials.The records of 105 patients who received placebo in 2 previous randomized clinical trials conducted by this group were reviewed. The proportion of patients who demonstrated clinical response to fatigue, defined as an increase in Functional Assessment of Chronic Illness Therapy-Fatigue score of [ge]7 from baseline to Day 8, a...
Source: Cancer - November 14, 2009 Category: Cancer & Oncology Authors: Maxine de la Cruz, David Hui, Henrique A. Parsons, Eduardo Bruera Source Type: journals

Modeling excess lung cancer risk among screened arm participants in the Mayo Lung ProjectEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Mayo Lung Project (MLP) was a randomized clinical trial designed to test whether periodic screening by chest x-ray reduced lung cancer (LC) mortality in men who were high-risk smokers. Among MLP participants, there were more deaths from LC in the screening arm both at the trial's end and after long-term follow-up. Overdiagnosis was cited widely as an explanation for the MLP results, whereas a role for excess LC risk attributable to undergoing numerous chest x-ray screenings largely was unexamined. The authors of this report examined the consistency of the MLP data with a modified 2-stage clonal expansion (TSCE) model o...
Source: Cancer - November 13, 2009 Category: Cancer & Oncology Authors: Deborah L. Goldwasser, Marek Kimmel Source Type: journals

Characteristics associated with early and late melanoma metastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, 2 potentially novel risk factors for melanoma metastases were identified, and different profiles of risk factors were constructed for EM versus LM. These differences may be important in future risk identification and stratification for clinical trials and for the management and treatment of patients with melanoma. Cancer 2010. © 2009 American Cancer Society. (Source: Cancer)
Source: Cancer - November 13, 2009 Category: Cancer & Oncology Authors: Jeremy A. Brauer, Cooper C. Wriston, Andrea B. Troxel, Rosalie Elenitsas, Daniel B. Shin, DuPont Guerry, Michael E. Ming Source Type: journals

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of the current study was to evaluate the feasibility and toxicity of radiation dose escalation with concurrent chemotherapy using helical tomotherapy (HT) in patients with inoperable, locally advanced, stage III nonsmall cell lung cancer (LANSCLC) (grading determined according to the American Joint Committee on Cancer 6th edition grading system).This phase 1/2 study was designed to determine the maximum tolerated dose (MTD) of radiotherapy in patients with LANSCLC administered concurrently with docetaxel and cisplatin. Radiotherapy was delivered using HT. A dose per fraction escalation was applied starting at...
Source: Cancer - November 13, 2009 Category: Cancer & Oncology Authors: Samuel Bral, Michaël Duchateau, Harijati Versmessen, Douwe Verdries, Benedikt Engels, Mark De Ridder, Koen Tournel, Christine Collen, Hendrik Everaert, Denis Schallier, Jacques De Greve, Guy Storme Source Type: journals

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some. We conducted a multicenter phase 2 trial to better define the clinical efficacy of thalidomide and temozolomide and the immune modulatory effects of thalidomide, when combined with temozolomide, in patients with metastatic melanoma.Patients must have had stage IV cutaneous melanoma, no active brain metastases, Zubrod PS 0-1, up to 1 prior systemic therapy excluding thalidomide, temozolomide, or dacarbazine, adequate organ functio...
Source: Cancer - November 13, 2009 Category: Cancer & Oncology Authors: Joseph I. Clark, James Moon, Laura F. Hutchins, Jeffrey A. Sosman, W. Martin Kast, Diane M. Da Silva, P. Y. Liu, John A. Thompson, Lawrence E. Flaherty, Vernon K. Sondak Source Type: journals

Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective was to determine whether antimullerian hormone (AMH) and inhibin B are such biomarkers. The authors tested whether AMH and inhibin B were impacted by breast cancer treatment by comparing cancer survivors to age-matched control women and determined the association between these hormones and postchemotherapy menstrual pattern.Breast cancer patients (n = 127) with American Joint Committee on Cancer stage I to III disease who were premenopausal at diagnosis were enrolled postchemotherapy and observed. The primary endpoint was chemotherapy-related amenorrhea (CRA) ([ge]12 months of amenorrhea after chemotherapy). ...
Source: Cancer - November 13, 2009 Category: Cancer & Oncology Authors: H. Irene Su, Mary D. Sammel, Jamie Green, Luke Velders, Corrie Stankiewicz, Jennifer Matro, Ellen W. Freeman, Clarisa R. Gracia, Angela DeMichele Source Type: journals

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study therefore aimed to assess the effect of this dose of vitamin D3 in patients with bone metastases from breast cancer.Patients with bone metastases treated with bisphosphonates were enrolled into this single-arm phase 2 study. Patients received 10,000 IU of vitamin D3 and 1000 mg of calcium supplementation each day for 4 months. The effect of this treatment on palliation, bone resorption markers, calcium metabolism, and toxicity were evaluated at baseline and monthly thereafter.Forty patients were enrolled. No significant changes in bone resorption markers were seen. Despite no change in global pain scales, there ...
Source: Cancer - November 13, 2009 Category: Cancer & Oncology Authors: Eitan Amir, Christine E. Simmons, Orit C. Freedman, George Dranitsaris, David E. C. Cole, Reinhold Vieth, Wei S. Ooi, Mark Clemons Source Type: journals

Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nurr1 belongs to a novel class of orphan nuclear receptors (the NR4A family). The authors have previously shown that Nurr1 is important in carcinogenesis. In the current study, they examined the clinicopathologic relevance of expression patterns of Nurr1 in bladder tumors.Nurr1 expression was determined using immunohistochemical staining in a bladder cancer tissue array (145 tumors). Tumors were classified according to Nurr1 protein levels in both cytoplasm and nucleus. Disease-specific survival and recurrence-free survival were investigated by Kaplan-Meier analysis and Cox proportional hazards analysis in multivariate mod...
Source: Cancer - November 12, 2009 Category: Cancer & Oncology Authors: Teruo Inamoto, Bogdan A. Czerniak, Colin P. Dinney, Ashish M. Kamat Source Type: journals

Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The authors successfully adopted an interesting and effective treatment for hepatocellular carcinoma (HCC) referred to as angiographic subsegmentectomy (AS). This treatment involved simultaneous embolization of the peripheral feeding artery and the portal vein. The result was that almost all of the HCC and peripheral liver parenchyma developed complete anatomic necrosis.To determine the effectiveness of this method, the authors retrospectively studied the local recurrence rates of 49 solitary HCCs and the long-term survival rates of 120 patients with HCC between 2000 and 2008.The results indicated that, in 31 small, solita...
Source: Cancer - November 11, 2009 Category: Cancer & Oncology Authors: Shozo Iwamoto, Taizo Yamaguchi, Osamu Hongo, Hideki Iwamoto, Hayato Sanefuji Source Type: journals

The role of postoperative radiotherapy for the treatment of gangliogliomasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, the authors compared 4 therapies for local control (LC) and overall survival (OS) in patients with ganglioglioma.In 402 patients with ganglioglioma, outcomes were compared for patients who underwent gross total resection alone (GTR) (n = 188), GTR plus radiotherapy (GTR + RT) (n = 21), subtotal resection alone (STR) (n = 113), and STR plus RT (STR + RT (n = 80). Age, sex, tumor site, and histologic grade also were investigated. Subgroup analyses were performed for both low-grade and high-grade tumors.The 10-year LC rates were 89% after GTR, 90% after GTR + RT, 52% after STR, and 65% after STR + RT (P < .001)...
Source: Cancer - November 11, 2009 Category: Cancer & Oncology Authors: Dirk Rades, Lena Zwick, Jan Leppert, Matteo M Bonsanto, Volker Tronnier, Juergen Dunst, Steven E. Schild Source Type: journals

Treatment patterns of aging Americans with differentiated thyroid cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The incidence of differentiated thyroid cancer (DTC) increases with age. Total thyroidectomy, often followed by radioactive iodine (RAI), is recommended for patients who have tumors that measure [ge]1 cm in greatest dimension. In the current study, the authors assessed the use of thyroidectomy and RAI among elderly patients with DTC and the effects on survival.Adults aged [ge]45 years with DTC [ge]1 cm in the Surveillance, Epidemiology, and End Results database from 1988 to 2003 were included. Bivariate and multivariate analyses were used to measure associations between demographic, clinical, and pathologic characteristics...
Source: Cancer - November 11, 2009 Category: Cancer & Oncology Authors: Henry S. Park, Sanziana A. Roman, Julie Ann Sosa Source Type: journals

Health status of the oldest adult survivors of cancer during childhoodEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, the authors assessed how treatment for childhood cancer affects older-adult health and health practices.One hundred seven adults treated for childhood cancer between 1947 and 1968, known to have survived past age 50 years, were identified from a single-institution cohort established in 1975. Updated vital status on eligible cases was obtained from public records. Survivors and a control group of their age-matched siblings and cousins completed a mailed survey to assess physical and social function, healthcare practices, and the prevalence of common adult illnesses.Of the 107 survivors known to be alive at ag...
Source: Cancer - November 11, 2009 Category: Cancer & Oncology Authors: Lisa B Kenney, Cheryl Medeiros Nancarrow, Julie Najita, Lynda M. Vrooman, Monica Rothwell, Christopher Recklitis, Frederick P. Li, Lisa Diller Source Type: journals

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this study was to investigate the efficacy of belotecan, a new camptothecin analog, combined with cisplatin for the treatment of chemotherapy-naive patients with extensive-disease small cell lung cancer (ED SCLC).Treatment consisted of belotecan 0.5 mg/m2 daily on Days 1 through 4 and cisplatin 60 mg/m2 on Day 1 of a 3-week cycle for up to 6 cycles unless there was disease progression, unacceptable toxicity, or patient refusal. Response assessment was done every 2 cycles using the Response Evaluation Criteria in Solid Tumors, and toxicity assessment was done every cycle using the National Cancer Institute ...
Source: Cancer - November 11, 2009 Category: Cancer & Oncology Authors: Dae Ho Lee, Sang-We Kim, Cheolwon Suh, Jung-Shin Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Im-Il Na, Jae Cheol Lee, Baek-Yeol Ryoo, Sung Hyun Yang Source Type: journals

Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal originEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Appendiceal neoplasms include tumors ranging from benign-appearing cells with widespread mucin deposits to aggressive poorly differentiated signet ring cell adenocarcinomas. Traditionally, these tumors are treated with cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy. For some patients, cytoreductive surgery is not an option, and minimal published data exist in the management and outcome of these patients. A retrospective analysis was conducted to determine the benefit of modern systemic chemotherapy in patients with disseminated appendiceal neoplasm who were not considered optimal candidates for...
Source: Cancer - November 10, 2009 Category: Cancer & Oncology Authors: Jamie F. Shapiro, Judy L. Chase, Robert A. Wolff, Laura A. Lambert, Paul F. Mansfield, Michael J. Overman, Aki Ohinata, Jun Liu, Xuemei Wang, Cathy Eng Source Type: journals

Mammographic density and the risk of breast cancer recurrence after breast-conserving surgeryEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Women with invasive breast cancer who are treated with breast-conserving surgery and radiotherapy face a cumulative risk of local disease recurrence of approximately 10% at 10 years. To the authors' knowledge, the role of mammographic density as a risk factor for the development of local recurrence has not been thoroughly evaluated to date.Medical records were reviewed for 335 patients who underwent breast-conserving surgery for invasive breast cancer and for whom a pretreatment mammogram was available. Information was recorded concerning mammographic density as well as tumor features, patient characteristics, and adjuvant...
Source: Cancer - November 9, 2009 Category: Cancer & Oncology Authors: Tulin Cil, Eve Fishell, Wedad Hanna, Ping Sun, Ellen Rawlinson, Steven A. Narod, David R. McCready Source Type: journals

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of the current study was to determine the prevalence of past HBV infection in patients with lymphoma and its relevance in terms of HBV-related complications.The authors reviewed 430 patients with lymphoma from May 2006 to May 2008.Among the 430 patients, 233 had both the HBsAg and HBcAb tests performed, whereas 197 had only the HBsAg test performed. Among those with both tests performed, 34.3% (80 of 233) were HBcAb positive only. Of these 80 patients, 58 had a concomitant HBV DNA level test, which was positive in 3 (5.2%). Of the 67 patients with past and 26 with chronic HBV infection who received chemothera...
Source: Cancer - November 7, 2009 Category: Cancer & Oncology Authors: Yu Xuan Koo, Daniel S. W. Tan, Iain B. Tan, Miriam Tao, Wan Cheng Chow, Soon Thye Lim Source Type: journals

Reply to The atypical Spitz tumor of uncertain biologic potentialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No abstract. (Source: Cancer)
Source: Cancer - November 6, 2009 Category: Cancer & Oncology Authors: Mathew W. Ludgate, Douglas R. Fullen, Lori Lowe, Timothy Johnson Source Type: journals

Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Human glioblastoma is a deadly brain cancer that continues to defy all current therapeutic strategies. The authors induced apoptosis in human glioblastoma T98G and U87MG cells after treatment with apigenin, (-)-epigallocatechin, (-)-epigallocatechin-3-gallate (EGCG), and genistein, which did not induce apoptosis in human normal astrocytes.Induction of apoptosis was examined using Wright staining and ApopTag assay. Production of reactive oxygen species (ROS) and increase in intracellular free Ca2+ were measured by fluorescent probes. Analysis of mRNA and Western blotting indicated increases in expression and activities of t...
Source: Cancer - November 6, 2009 Category: Cancer & Oncology Authors: Arabinda Das, Naren L. Banik, Swapan K. Ray Source Type: journals

Where does the combination of sorafenib and interferon in renal cell carcinoma stand?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sorafenib can be combined safely with interferon, but the results of a recent randomized, phase 2 trial cast doubt on the value of further evaluating this combination. The renal cell carcinoma field continues to wrestle with the value of combining "targeted" therapies with cytokines. (Source: Cancer)
Source: Cancer - November 4, 2009 Category: Cancer & Oncology Authors: Keith T. Flaherty Source Type: journals

Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer riskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Protein phosphatase 2A (PP2A) is a major cellular phosphatase and plays key regulatory roles in growth, differentiation, and apoptosis. Women who are diagnosed with benign proliferative breast disease are at increased risk for the subsequent development of breast cancer.The authors evaluated genetic variation of PP2A holoenzyme subunits for their potential contribution to breast cancer risk. A nested case-control investigation was performed on a cohort of women who had a history of benign breast disease. The women were followed for an average of 18 years, and DNA prepared from the original archival benign breast biopsy (19...
Source: Cancer - November 4, 2009 Category: Cancer & Oncology Authors: William D. Dupont, Joan P. Breyer, Kevin M. Bradley, Peggy A. Schuyler, W. Dale Plummer, Melinda E. Sanders, David L. Page, Jeffrey R. Smith Source Type: journals

An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Preoperative chemotherapy for hepatic resection of colorectal liver metastases is associated with the development of chemotherapy-associated steatohepatitis (CASH). This increases the risk of perioperative morbidity and mortality. To the authors' knowledge, an animal model for CASH has not been described previously. It has been established that fatty acid bile acid conjugates (FABACs) prevent the formation of diet-induced fatty liver. The current study was designed to establish an animal model of CASH and to use that model to study the effect of FABACs on its occurrence.C57BL/6 mice were given different doses of oxaliplati...
Source: Cancer - November 4, 2009 Category: Cancer & Oncology Authors: Daniel Keizman, Natalie Maimon, Maya Ish-Shalom, Dana Buchbut, Moshe Inbar, Baruch Klein, Joelle Bernheim, Ilana Goldiner, Alicia Leikin-Frenkel, Fred Konikoff Source Type: journals

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma.Eligible patients (N = 100, ages 31-84 years) received bendamustine at a dose of 120 mg/m2 by intravenous infusion on Days 1 and 2 every 21 days for 6 to 8 cycles. Histologies included follicular (62%), small lymphocytic (21%), and marginal zone (16%) lymphomas. Patients had received a median of 2 previous regimens (range, 0-6 previous regimens), and 36%were refractory to their most recent chemotherapy ...
Source: Cancer - November 4, 2009 Category: Cancer & Oncology Authors: Brad S. Kahl, Nancy L. Bartlett, John P. Leonard, Ling Chen, Kristen Ganjoo, Michael E. Williams, Myron S. Czuczman, K. Sue Robinson, Robin Joyce, Richard H. van der Jagt, Bruce D. Cheson Source Type: journals

Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Procalcitonin has been well established as an important marker of sepsis and systemic infection. The authors evaluated the diagnostic and predictive value of calcitonin and its prohormone procalcitonin in medullary thyroid cancer.The authors systematically explored the ability of calcitonin and procalcitonin to identify medullary thyroid cancer and predict the endpoints local recurrence and distant metastases, as well as the progression-free survival. Patients with C-cell hyperplasia; patients after thyroidectomy for differentiated thyroid cancer, goiter, or Graves disease; and healthy subjects served as controls. The stud...
Source: Cancer - November 4, 2009 Category: Cancer & Oncology Authors: Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller-Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links, Beat Müller Source Type: journals

Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Poor expression of microRNAs (miRs) reportedly plays an important role in gastric carcinogenesis. Large-scale microarray assays have indicated that there is significant down-regulation of miR-218 in gastric cancer. miR-218 also was decreased specifically in human papillomavirus-positive cell lines, cervical lesions, and cervical cancer tissues and in bronchial airway epithelium in smokers. However, its role in carcinogenesis remains unclear, especially in Helicobacter pylori (H. pylori)-associated gastric cancer.miR-218 levels were evaluated in 20 noncardia gastric cancer tissues, in 10 H. pylori-infected and 8 uninfected ...
Source: Cancer - November 4, 2009 Category: Cancer & Oncology Authors: Caiping Gao, Zhiyu Zhang, Wenzhong Liu, Shudong Xiao, Weiqi Gu, Hong Lu Source Type: journals

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed.In phase 1 and pilot studies, the authors evaluated the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a 5-day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory AML. The cladribine dose was escalated as follows: 9.1, 13.6, 16.3, and 19.5 mg/m2 per day (8.9 mg/m2 per day in the pilot study). Outcome was analyzed according to the absence (Stratum 1) versus presence (Stratum 2) of previous allogeneic hematopoietic stem cell transplant...
Source: Cancer - November 4, 2009 Category: Cancer & Oncology Authors: Hiroto Inaba, Clinton F. Stewart, Kristine R. Crews, Shengping Yang, Stanley Pounds, Ching-Hon Pui, Jeffrey E. Rubnitz, Bassem I. Razzouk, Raul C. Ribeiro Source Type: journals

Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report here that B-cell translocation gene 3 (BTG3) is transcriptionally down-regulated in prostate cancer and the mechanism of inactivation is through promoter hypermethylation.Prostate cancer and normal cell lines were treated with different doses of genistein and 5-aza-2[prime]-deoxycytidine (5Aza-C). BTG3 messenger ribonucleic acid (mRNA) expression was determined by quantitative real-time polymerase chain reaction in tissues and cell lines. Bisulfate-modified polymerase chain reaction, cloning and sequencing were used to examine promoter methylation in tumor samples and cell lines. Enzyme activity/inhibition assays...
Source: Cancer - November 2, 2009 Category: Cancer & Oncology Authors: Shahana Majid, Altaf A. Dar, Varahram Shahryari, Hiroshi Hirata, Ardalan Ahmad, Sharanjot Saini, Yuichiro Tanaka, Angela V. Dahiya, Rajvir Dahiya Source Type: journals

Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The authors sought to determine the incidence and severity of cardiovascular toxicity caused by imatinib mesylate in gastrointestinal stromal tumor (GIST) and other sarcoma patients, and to explore cardiotoxicity caused by imatinib mesylate using cell culture and in vitro models.To determine the incidence and significance of serious cardiac adverse events in GIST and other sarcoma patients receiving imatinib mesylate, the authors performed a retrospective analysis of 219 consecutive patients treated with imatinib mesylate. In vitro studies of imatinib mesylate on cultured cardiomyocytes and biochemical studies of cardiac l...
Source: Cancer - November 2, 2009 Category: Cancer & Oncology Authors: Jonathan C. Trent, Shalin S. Patel, Jianhu Zhang, Dejka M. Araujo, Juan-Carlos Plana, Daniel J. Lenihan, Dominic Fan, Shreyaskumar R. Patel, Robert S. Benjamin, Aarif Y. Khakoo Source Type: journals

Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene are common in white persons and are associated with pancreatic disease. The purpose of this case-control study was to determine whether CFTR mutations confer a higher risk of pancreatic cancer.In a case-control study, the authors compared the rates of 39 common cystic fibrosis-associated CFTR mutations between 949 white patients with pancreatic adenocarcinoma and 13,340 white controls from a clinical laboratory database for prenatal testing for CFTR mutations. The main outcome measure was the CFTR mutation frequency in patients and controls.Ov...
Source: Cancer - November 2, 2009 Category: Cancer & Oncology Authors: Robert R. McWilliams, Gloria M. Petersen, Kari G. Rabe, Leonard M. Holtegaard, Pamela J. Lynch, Michele D. Bishop, W. Edward Highsmith Jr Source Type: journals

Preoperative assessment enables the early detection and successful treatment of lymphedemaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No abstract. (Source: Cancer)
Source: Cancer - October 29, 2009 Category: Cancer & Oncology Authors: Sandi Hayes, Bruce Cornish, Beth Newman Source Type: journals

Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In a long-term retrospective immunohistochemical study of adenoid cystic carcinoma (ACC) of salivary gland, we investigated the relation of p63 immunodetection to prognosis. Although it is generally agreed that the solid pattern is the most aggressive pattern of growth, ACCs with predominantly cribriform or tubular patterns have an unpredictable clinical course, with a relatively favorable 5-year survival but a low 20-year survival.Formalin-fixed paraffin sections from 35 cases of ACC showing a predominantly better differentiated histopathology, ie, cribriform or tubular patterns of growth, were immunostained for p63. Auto...
Source: Cancer - October 28, 2009 Category: Cancer & Oncology Authors: Naomi Ramer, HaiShan Wu, Edmond Sabo, Yael Ramer, Patrick Emanuel, Lurmag Orta, David E. Burstein Source Type: journals

Disparities in medical care among commercially insured patients with newly diagnosed breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
African-American women have increased breast cancer mortality compared with white women. Diagnostic and treatment gaps may contribute to this disparity.In this retrospective, longitudinal cohort study, Southern US health plan claims data and linked medical charts were used to identify racial disparities in the diagnoses, treatment, and mortality of commercially insured women with newly diagnosed breast cancer. White women (n = 476) and African-American women (n = 99) with newly diagnosed breast cancer were identified by breast cancer claims codes (International Classification of Diseases, Ninth Revision, Clinical Modificat...
Source: Cancer - October 28, 2009 Category: Cancer & Oncology Authors: Louise J. Short, Maxine D. Fisher, Peter M. Wahl, Monique B. Kelly, Grant D. Lawless, Sandra White, Nancy A. Rodriguez, Vincent J. Willey, Otis W. Brawley Source Type: journals

Primary plasma cell leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(PCL) is a rare plasma cell disorder, and current knowledge regarding survival in this disease is limited to small series of patients. Although there has been significant improvement in the survival of patients with multiple myeloma (MM) over the past few decades, it is not known whether there has been a similar trend for PCL.The authors analyzed the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the characteristics and survival of patients who had PCL compared with those of patients who had MM.Among 291 patients with PCL, the median age was 67 years (range, 19-98 years), the distribution of men a...
Source: Cancer - October 28, 2009 Category: Cancer & Oncology Authors: Giridharan Ramsingh, Paul Mehan, Jingqin Luo, Ravi Vij, Daniel Morgensztern Source Type: journals